C4 Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 10, 2021 and accepted by EDGAR at Nov 10, 2021, 16:27 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-07-01 to 2021-09-30 | $24.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-09-30 | $68.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$24.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$66.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$24.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$68.2m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | −$0.51 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | −$1.51 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$61.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $162.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $412.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $507.9m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $48.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $109.1m | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $10.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2021-09-30 | $398.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-056223. Last ingested by Listed: Nov 14, 2026, 19:39 ET. Listed shows no prices and gives no investment advice.